
Quantum Delta NL

Challenge based funding 2025

July 8th, 2025





What to expect today


- Introduction to challenge-based funding by QDNL
- Learn about the objectives of the first call for Life Science & Health
- Get the latest information on the project proposals we are looking for
- Current timeline for this call
- Q&A, we are interested to hear your thoughts and ideas





OUANTUMDELTA.NL

QDNL Challenge based funding – context and status



- QuantumDelta Phase 3 targets to engage
 the perspectives of End users and
 Manufacturing
- Supported by this new Challenge Based
 Approach
- This is the pilot challenge focusing on End

 Users perspective in Life Science and Health

Vision and Strategic Ambition

- Build on QDNL Program: Catalyst Programs and Action Lines in Phases 1 and 2
- New interdisciplinary collaborations in Quantum Life sciences & Health
- Develop and demonstrate quantum powered solutions that address bottlenecks in LSH
- Lay foundation for real-world deployment of Quantum enabled solutions in LSH
- Two phases
 - Step 1: solid foundation
 - Step 2: make impact





This Challenge

Can Quantum technologies solve challenges in Life Science&Health with measurable, near-term progress towards real-world utility?

- . Drug discovery bottlenecks
- . Biomarker detection and sensing
- . Clinical decision support or scheduling optimization
- . Medical data trust and security
- . Personalized digital therapeutics

These examples are illustrative



QUANTUMDELTA.NL

Challenge based funding – Step 1

Expected Duration: Up to 12 months

Expected total Budget: €2M

What we find important:

- . Clarity of the defined use case and relevance to LSH bottlenecks
- . Well-reasoned quantum advantage hypothesis (e.g., NISQ, FTQC, sensing, QKD)
- . Scientific and technical credibility of the approach
- . Target engagement with relevant end-users/LSH partners (e.g., hospital, pharma, data partner)
- . Quality of the execution plan and risk mitigation strategy

We aim for impactful funding

- . Assess funded projects regularly and closely
- . Steer on output
- . Reshape, consolidate or discontinue

Challenge based funding – Step 2

Duration indication: Up to 24 months

Budget indication (total): €5M

What we find important:

- . Proven technical feasibility and performance (Step 1)
- . Clear stakeholder support and co-funding commitment from LSH partner(s)
- . Integration potential within existing healthcare systems or workflows
- . Realistic go-to-market or adoption roadmap
- . Alignment with national innovation and procurement priorities
- . Demonstrate team competences, IP strategy and preparing for market entry

We aim for impactful funding

- . Assess funded projects regularly and closely
- . Steer on output
- . Reshape, consolidate or discontinue

Quantum Delta NL

What we are looking for

☑ What We Are Looking For	X What Doesn't Fit
Disruptive, high-risk quantum approaches to	Incremental enhancements to existing
real Life science and Health bottlenecks	quantum or classical approaches
Proposals with clear quantum advantage	General research without application focus
hypotheses (NISQ, FTQC, sensing)	
End-user-engaged projects (clinics, pharma,	Academic-only consortia with no engagement
medtech, etc) from the outset	beyond research
Interdisciplinary teams across quantum,	Isolated efforts with limited technical or clinical
engineering, and healthcare domains	reach
Roadmaps towards early demonstrators, risk	Vague or purely theoretical objectives lacking
analysis, and valorisation and	measurable outcomes
commercialisation pathways	
Proposals that strengthen the Dutch quantum	Narrow proposals without ecosystem-building
ecosystem and attract external collaboration	relevance



Q&A


1.On the challenges:


Do you recognize the challenges?

Are we missing certain challenges?

2.Any other questions







Next steps

- Reach out to us: funding@quantumdelta.nl
- Provide feedback and questions
- Engage in matchmaking
- Contact Richard van Harderwijk, QDNL business developer for LSH Richard.vanHarderwijk@quantumdelta.nl
- Stay up to date: QDNL newsletter

